For research use only. Not for therapeutic Use.
Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins[1]. Hematin can be used for the research of acute porphyrias and cancer[1][2][3][4][5].
Hematin (0.01 mg/ml) inhibits the clotting of bovine fibrinogen (1.3 to 2.6 mg/ml) by bovine thrombin (0.12 U/ml) and inhibits the hydrolysis of a synthetic substrate by human thrombin[2].
Hematin (0.035 mg/ml) reduces VIII:C activity from 0.88 to 0.40 U/ml[2].
Hematin (0.05 mg/ml) inhibits the activation of VIII:C by thrombin (0.04 U/ml)[2].
Hematin (0.09 mg/ml) inhibits the hydrolysis of a synthetic substrate by plasmin[2].
Hematin (i.v.; single injection) suppressed porphyrin production in SD rat (weighing 160-205 g)[4].
| Catalog Number | M079273 |
| CAS Number | 15489-90-4 |
| Synonyms | 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(3+);hydroxide |
| Molecular Formula | C34H33FeN4O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C34H34N4O4.Fe.H2O/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);;1H2/q;+3;/p-3 |
| InChIKey | BMUDPLZKKRQECS-UHFFFAOYSA-K |
| SMILES | CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[OH-].[Fe+3] |
| Reference | [1]. Siegert SW, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther. 2008 Sep;25(9):842-57. [2]. Green D, et al. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361-369. [3]. Amin ML, et al. Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. Eur J Pharm Sci. 2016 Aug 25;91:138-43. [4]. Goetsch C, et al. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235-238. [5]. Quadros HC, et al. The Role of the Iron Protoporphyrins Heme and Hematin in the Antimalarial Activity of Endoperoxide Drugs. Pharmaceuticals (Basel). 2022;15(1):60. Published 2022 Jan 4. |
